Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural validity of the Pain Interference Questionnaire and Fear of Pain Questionnaire for children and young people with cerebral palsy.

Developmental medicine and child neurology·2025
Same author

Targeted deletion of Cyp24a1 in the intestine reduces mucosal injury and preserves epithelial proliferation after 5-fluorouracil treatment.

The Journal of steroid biochemistry and molecular biology·2025
Same author

Adapting two pain assessment tools for young people with cerebral palsy: a multi-stakeholder consensus study.

Pain reports·2025
Same author

A systematic review and meta-analysis on the efficacy of fecal microbiome transplantation in patients with severe alcohol-associated hepatitis.

European journal of gastroenterology & hepatology·2025
Same author

The comprehensibility and feasibility of the modified brief pain inventory and fear of pain questionnaire adapted for children and young people with cerebral palsy.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2025
Same author

Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2024
Same journal

Cortical and brainstem mechanisms of pain: linking defensive responses, descending modulation, and affective-sensory integration.

Current opinion in supportive and palliative care·2026
Same journal

Comparison of the EORTC QLQ-EN24, FACT-En, and FEnSI-23 for assessing quality of life in endometrial cancer: a systematic review.

Current opinion in supportive and palliative care·2026
Same journal

Dysphagia, aspiration, and respiratory problems in people with chronic respiratory illness.

Current opinion in supportive and palliative care·2026
Same journal

Decision-making and treatment planning for older adults with pre-existing cognitive impairment and cancer.

Current opinion in supportive and palliative care·2026
Same journal

Clinical decision support system for breathlessness.

Current opinion in supportive and palliative care·2026
Same journal

The prevalence of persisting breathlessness despite treatment in chronic conditions.

Current opinion in supportive and palliative care·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Chemotherapy-induced diarrhoea.

Rachel J Gibson1, Andrea M Stringer

  • 1Discipline of Anatomical Sciences, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. rachel.gibson@adelaide.edu.au

Current Opinion in Supportive and Palliative Care
|April 15, 2009
PubMed
Summary
This summary is machine-generated.

Chemotherapy-induced diarrhea, a common side effect, is gaining research attention. Recent studies explore new treatments and mechanisms, offering hope for better patient management.

Related Experiment Videos

Last Updated: Jun 24, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Diarrhea is a significant manifestation of chemotherapy-induced mucositis.
  • The underlying mechanisms of chemotherapy-induced diarrhea are not well understood.
  • Recent research has begun to address this knowledge gap.

Purpose of the Study:

  • To review recent laboratory and clinical studies on chemotherapy-induced diarrhea.
  • To elucidate effective treatment options for this condition.
  • To examine the current understanding of its underlying mechanisms.

Main Methods:

  • Literature review of recent laboratory and clinical studies.
  • Analysis of emerging treatment strategies.
  • Synthesis of current knowledge on disease mechanisms.

Main Results:

  • Numerous new treatment options for chemotherapy-induced diarrhea have been trialed.
  • Some promising treatments require further investigation in larger clinical trials.
  • Advancements in understanding the mechanisms of chemotherapy-induced diarrhea have been made.

Conclusions:

  • Current understanding of chemotherapy-induced diarrhea mechanisms is evolving.
  • New and existing treatment options are being presented.
  • There is a discernible shift towards more effective research in this area.